Antikor is a privately-held biotechnology company originally spun-out from Imperial College. We specialise in the discovery and development of small-format Antibody (Fragment) Drug Conjugates, known as FDCs. FDCs are a form of targeted cytotoxic chemotherapy combining the specificity of antibodies with the potency of small-molecule chemotherapy drugs. Specifically, FDCs are smaller than conventional Antibody Drug Conjugates (ADCs) meaning better tumour penetration and more rapid systemic clearance, potentially leading to a higher clinical therapeutic index. Antikor are developing the next-generation of solid tumour therapies, with a major interest in gastro-intestinal cancers.

Biotechnology

Life Sciences

Antikor Biopharma Ltd

Antikor Biopharma Ltd's headquarters in Stevenage, United Kingdom

Mahendra Deonarain

This department focuses on the advancement of scientific knowledge and the development of new products through research and experimentation.

Antikor Biopharma Ltd

Org chart

Teams

Research and Development

Offices

Antikor Biopharma Ltd

Org chart

Teams

Research and Development

Offices

Related companies